The second-line triple combinations anti-CTLA-4 + cabozantinib + chidamide-k30 tumor treatment upregulated the response to IFN-γ, cellular response to IFN-γ, adaptive immune response gene signatures, cell chemotaxis and leukocyte migration gene signatures; however, it downregulated angiogenesis gene signature (Figure 6F; p < 0.05). Here, IFNG is linked to neoplasm.